<?xml version="1.0" encoding="UTF-8"?>
<xml>
  <records>
    <record>
      <source-app name="Horizon">Horizon</source-app>
      <rec-number>1</rec-number>
      <foreign-keys>
        <key app="Horizon" db-id="fdi:010087122">1</key>
      </foreign-keys>
      <ref-type name="Journal Article">17</ref-type>
      <work-type>ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES</work-type>
      <contributors>
        <authors>
          <author>
            <style face="normal" font="default" size="100%">Dechavanne, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Srivastava, A.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Gangnard, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Nunes-Silva, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Dechavanne, C.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Fievet, Nadine</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Deloron, Philippe</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Chene, A.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Gamain, B.</style>
          </author>
        </authors>
      </contributors>
      <titles>
        <title>Parity-dependent recognition of DBL1X-3X suggests an important role of the VAR2CSA high-affinity CSA-binding region in the development of the humoral response against placental malaria</title>
        <secondary-title>Infection and Immunity</secondary-title>
      </titles>
      <pages>2466-2474</pages>
      <dates>
        <year>2015</year>
      </dates>
      <call-num>fdi:010087122</call-num>
      <language>ENG</language>
      <periodical>
        <full-title>Infection and Immunity</full-title>
      </periodical>
      <isbn>0019-9567</isbn>
      <accession-num>ISI:000356243000024</accession-num>
      <number>6</number>
      <electronic-resource-num>10.1128/iai.03116-14</electronic-resource-num>
      <urls>
        <related-urls>
          <url>https://www.documentation.ird.fr/hor/fdi:010087122</url>
        </related-urls>
        <pdf-urls>
          <url>https://www.documentation.ird.fr/intranet/publi/2023-02/010087122.pdf</url>
        </pdf-urls>
      </urls>
      <volume>83</volume>
      <remote-database-provider>Horizon (IRD)</remote-database-provider>
      <abstract>Plasmodium falciparum multidomain protein VAR2CSA stands today as the leading vaccine candidate against pregnancy-associated malaria (PAM). Most of the studies aiming to decrypt how naturally acquired immunity develops have assessed the immune recognition of individual VAR2CSA Duffy-binding-like (DBL) domains, thus overlooking the presence of conformational epitopes resulting from the overall folding of the full-length protein. In order to characterize the development of humoral immunity toward VAR2CSA, we made use of a large cohort of 293 Senegalese pregnant women to assess the level of recognition by plasma IgG of the full-length VAR2CSA protein of the 3D7 parasite strain (3D7-VAR2CSA), the CSA-binding multidomains 3D7-DBL1X to -DBL3X (3D7-DBL1X-3X), and the CSA nonbinding multidomains 3D7-DBL4 epsilon to -DBL6 epsilon (3D7-DBL4 epsilon-6 epsilon), as well as individual 3D7-DBL domains. Our results revealed a parity-dependent recognition of the full-length 3D7-VAR2CSA and of the CSA-binding region, 3D7-DBL1X-3X. Indeed, multigravid women possess significantly higher levels of antibodies directed against these constructs than primigravidae. Our results suggest an important role of antibodies targeting the CSA-binding region in the development of immunity against PAM, therefore providing new insights on how natural protection might be acquired and further information for the design of VAR2CSA-based vaccines.</abstract>
      <custom6>050 ; 052</custom6>
      <custom1>UR216</custom1>
    </record>
  </records>
</xml>
